VIM-positive Pseudomonas aeruginosa in a large tertiary care hospital: matched case-control studies and a network analysis

Antimicrobial Resistance and Infection Control
Anne F Voor In 't HoltMargreet C Vos

Abstract

Emergence of multidrug-resistant Pseudomonas aeruginosa is of global concern. We aimed to identify epidemiological relationships, the most common way of transmission, and risk factors for presence of Verona Integron-encoded Metallo-β-lactamase (VIM)-positive P. aeruginosa (VIM-PA). We conducted a network analysis and matched case-control studies (1:2:2). Controls were hospital-based and matched with cases for ward, day of admission (control group 1 and 2) and time between admission and the identification of VIM-PA (control group 1). The network was visualized using Cytoscape, and risk factors were determined using conditional logistic regression. Between August 2003 and April 2015, 144 case patients and 576 control patients were recruited. We identified 307 relationships in 114 out of these 144 patients, with most relationships (84.7%) identified at the same department < 3 months after a previous case patient was discharged. In the multivariable model, having undergone ≥1 gastroscopy (odds ratio [OR] = 4.40, 95% confidence interval [CI] = 2.00 to 9.65 and OR = 2.47; 95% CI = 1.12 to 5.49), > 10 day use of selective digestive tract decontamination (SDD) (OR = 2.97; 95% CI = 1.02 to 8.68 and OR = 4.61; 95% CI = 1.22 to 17.37), an...Continue Reading

References

May 21, 1999·Archives of Internal Medicine·Y CarmeliM H Samore
Apr 16, 2005·Clinical Microbiology Reviews·Timothy R WalshPatrice Nordmann
Dec 3, 2008·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Susy HotaMichael A Gardam
Jan 2, 2009·The New England Journal of Medicine·A M G A de SmetM J M Bonten
Mar 13, 2010·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Cristina SuárezJavier Ariza
Dec 7, 2010·International Journal of Antimicrobial Agents·Timothy R Walsh
Jul 19, 2012·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A K Van der BijUNKNOWN MBL-PA Surveillance Study Group
Apr 9, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M KnoesterK E Veldkamp
Jul 15, 2015·Infection & chemotherapy·Duck Jin HongKyungwon Lee
Sep 12, 2015·Endoscopy International Open·Nikki KentersAndreas Voss
Dec 18, 2015·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Barbara AlbigerUNKNOWN European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group

❮ Previous
Next ❯

Citations

Jun 28, 2019·Antimicrobial Resistance and Infection Control·Marjolein C PersoonJuliëtte A Severin
Feb 6, 2020·Antimicrobial Resistance and Infection Control·Marjolein C PersoonJuliëtte A Severin
Jan 30, 2020·Nature Communications·Kelly E R BachtaAlan R Hauser
Oct 31, 2020·Scientific Reports·Philipp KohlerUNKNOWN Toronto Invasive Bacterial Diseases Network (TIBDN)

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

R Project for statistical computing
DiversiLab
PA
GraphPad
GraphPad Prism
SPSS
Cytoscape
VIM

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

© 2022 Meta ULC. All rights reserved